What’s Going On With Tempus AI Stock on Monday?
Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.
Read original at benzingaStocks · News reference
Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For
MRK, MRNA's cancer vaccine breakthrough could revive the mRNA trade, putting biotech and genomics ETFs back in focus.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 19, 2026, 9:49 PM
- Checked
- Aug 19, 2026, 9:49 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Bitcoin Tops $80,000, Oil Sinks As Navy Clears Hormuz Mines: Stock Market Today
Wall Street clawed back Monday's AI selloff as Brent slid below $90 and 10-year yields eased from 20-month highs.
Read original at benzingaMemory Stocks Slide as Trump Threatens 50% Tariffs on Canadian Autos, Steel in 2027: Stock Market Today
US equities mixed as tech stocks drag Nasdaq 100 lower, Trump escalates trade fight with Canada, and Fed Chair Warsh speaks at Jackson Hole.
Read original at benzingaBessent's Bond Rescue Fizzles, Walmart Craters 9%: Stock Market Today
Long-end Treasury yields snapped back toward 20-month highs; Walmart posted its worst session in four years.
Read original at benzingaBiotech Is Booming, But These 2 Stocks Missed the Memo
The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.
Read original at benzingaSMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.
Read original at zacks-investment-research